Rocket Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Rocket Pharmaceuticals announces its 2026 Annual Meeting, seeking approval for director elections, auditor ratification, executive compensation, and a stock option exchange program.
NASDAQ
Rocket Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
Rocket Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.
NASDAQ
Rocket Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Rocket Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on key proposals including the election of directors and an increase in authorized common stock.